Binding with serum components favorably affects cellular uptake of 111In-oligonucleotide in a leukemia cell line

Cancer Biother Radiopharm. 2006 Feb;21(1):34-40. doi: 10.1089/cbr.2006.21.34.

Abstract

Purpose: The influence of serum components on the intracellular uptake of an 111In-oligonucleotide (ODN) against mdr1 mRNA was investigated in the murine leukemia cell line, P388/S, and its mdr1-overexpressed P388/R.

Methods: 111In-ODNs naked and vectorized with lipids were analyzed for binding with serum components using high-performance liquid chromatography (HPLC). 111In-ODN was incubated in albumin and transferrin solutions. 111In-DTPA and 111In-mononucleotide were incubated in serum. Degradation of naked 111In-ODN was detected in phosphate buffered saline (PBS) and serum containing endonuclease S1. Cellular uptakes of naked and vectorized 111In-ODN in the above cells were examined with and without fetal calf serum (FCS).

Results: Time-dependent binding of naked and vectorized 111In- ODN with serum components was observed throughout 24 hours. Transchelation of 111In to transferrin was not detected. HPLC profiles of 111In-DTPA and 111In-mononucleotide did not change in serum. Degradation of 111In-ODN by S1 was less remarkable in serum than in PBS. Specific accumulation of vectorized 111In-ODN in P388/R cells was achieved in culture with and without 10% FCS.

Conclusions: This study verified the intense binding of ODN with serum components, leading to no inhibition on ODN intracellular specific uptake. Binding with serum components protects 111In-ODN from degradation by endonuclease and thus may facilitate ODN transmembrane delivery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biological Transport
  • Cell Line, Tumor
  • Doxorubicin / toxicity
  • Drug Resistance, Neoplasm
  • Humans
  • Indium Radioisotopes / pharmacokinetics*
  • Indium Radioisotopes / therapeutic use
  • Kinetics
  • Leukemia P388 / metabolism*
  • Leukemia P388 / radiotherapy
  • Mice
  • Oligodeoxyribonucleotides / blood
  • Oligodeoxyribonucleotides / pharmacokinetics*
  • Oligodeoxyribonucleotides / therapeutic use

Substances

  • Indium Radioisotopes
  • Oligodeoxyribonucleotides
  • Doxorubicin